Physician profile
Paul Brown
NPI 1588628705
$2,453.74
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,831 · 2020: $622.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $336.42 | 2019-2020 | |
| Allergan, INC. | $252.83 | 2019-2020 | |
| Pfizer INC. | $237.18 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.87 | 2019-2020 | |
| Glaxosmithkline, LLC. | $198.96 | 2019-2020 | |
| Lilly USA, LLC | $185.42 | 2019-2020 | |
| Novo Nordisk INC | $175.05 | 2019-2020 | |
| Amgen INC. | $131.25 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $111.87 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.31 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $95.66 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $88.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.89 | 2019 | |
| Astellas Pharma US INC | $62.97 | 2019 | |
| Merck Sharp & Dohme LLC | $48.15 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $46.28 | 2019 | |
| Amarin Pharma, INC. | $31.23 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.01 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.72 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.